Oncotarget

Meta-Analysis:

Systematic review and meta-analysis of the efficacy of breast conservation therapy followed by radiotherapy in four breast cancer subtypes

Xin-Bin Pan, Rou-Jun Chen, Shi-Ting Huang, Yan-Ming Jiang and Xiao-Dong Zhu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:57414-57420. https://doi.org/10.18632/oncotarget.18205

Metrics: PDF 1928 views  |   HTML 2021 views  |   ?  


Abstract

Xin-Bin Pan1, Rou-Jun Chen1, Shi-Ting Huang1, Yan-Ming Jiang1 and Xiao-Dong Zhu1

1Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China

Correspondence to:

Xiao-Dong Zhu, email: [email protected]

Keywords: breast cancer, molecular subtypes, breast conservation therapy, radiotherapy

Received: September 30, 2016    Accepted: May 08, 2017    Published: May 24, 2017

ABSTRACT

The different molecular subtypes of breast cancer are associated with distinct outcomes. We assessed the efficacy of breast conservation therapy (BCT) followed by radiotherapy for patients with different breast cancer subtypes. We searched the MEDLINE, EMBASE, and Cochrane Library databases to identify studies published prior to April 30, 2016 that assessed the efficacy of BCT followed by radiotherapy in breast cancer patients with different molecular subtypes. A meta-analysis of seven studies that included 3,798 luminal A, 770 luminal B, 344 human epidermal growth factor receptor 2 (Her-2), and 767 triple-negative breast cancer (TNBC) patients was performed. The pooled odds ratio [OR] for local relapse-free survival in luminal A compared to Her-2 patients was 0.1960 (95% confidence interval [CI]: 0.0440–0.8728, p = 0.0325) at 5 years and 0.2592 (95% CI: 0.1301–0.5167, p = 0.0001) at 10 years. The pooled OR for local-regional relapse-free survival in luminal A compared to TNBC patients was 0.1381 (95% CI: 0.0565–0.3374, p = 0.0000) at 5 years and 0.1221 (95% CI: 0.0182–0.8192, p = 0.0304) at 10 years. Thus, the rate of local-regional control is higher in luminal A patients than in Her-2 or TNBC patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18205